GW Cannabinoid Platform

Cannabinoid Science

The world has only recently started to recognize the true potential of cannabinoid science to bring FDA-approved medicines to patients in a new frontier of medicine.

Cannabinoids interact with many neurotransmitter and neuromodulator systems in the human body, offering the potential to meet currently unmet needs of patients in multiple treatment areas. Through our GW Cannabinoid Platform and research into endocannabinoids, Jazz is particularly well positioned at exploring cannabinoid-based therapeutic prospects.

At Jazz, we seek solutions for rare or complex diseases, and work to make those solutions available to the often-overlooked patients who need them. In 2021, we acquired GW Pharmaceuticals and integrated two teams with a shared vision of developing innovative and differentiated therapies that advance science and caring about patients with often-overlooked diseases.

As a leader in cannabinoid science and the first and only company to receive a U.S. Food and Drug Administration (FDA) approval for a plant-derived cannabinoid medicine, GW Pharmaceuticals brings a deep scientific understanding of the pharmacological effects, unique formulation, rigorous clinical testing and regulated manufacturing process of this growing treatment category.

We are excited to build an even stronger company together and look forward to the greater impact we will continue to drive for patients, caregivers, health care providers, and other stakeholders in the cannabinoid space.

Jazz’s existing early-stage research into endocannabinoid therapies, combined with the industry-leading GW Cannabinoid Platform, has expanded and diversified our commercial portfolio and growing neuroscience pipeline into several therapeutic areas. To learn more about Jazz’s neuroscience pipeline, please visit here.

GW Cannabinoid Platform

Cannabinoid science has opened the door to the development of FDA-approved plant-derived cannabinoid medications that are used to treat a number of neurological diseases. Over more than two decades, GW Pharmaceuticals, now a part of Jazz Pharmaceuticals, has established an industry-leading cannabinoid science platform to develop a deep, innovative pipeline of early and late-stage cannabinoid product candidates and highly specialized growing and manufacturing expertise.

As a pioneer in this emerging treatment area, GW successfully trailblazed to enable the development, manufacture, and commercialization of regulatory approved plant-derived cannabinoid medicines with the potential to transform the lives of patients and their families. Through these committed efforts, GW developed and commercialized the world’s first prescription medicine derived from the cannabis plant. To learn more about international cannabinoid science, please visit https://www.cannabinoideducation360.com/.

Unlike non-FDA-approved cannabidiol products or cannabis-derived products, GW’s regulatory-approved portfolio ensures that every product manufactured has a safety and efficacy profile that has been thoroughly evaluated in clinical trials, independently peer-reviewed, approved by regulatory authorities (FDA, MHRA, etc.), and consistently manufactured to ensure the highest quality standards are met.

At Jazz Pharmaceuticals, we passionately believe in the therapeutic potential of cannabis-based medicines to bring effective new treatment options to patients worldwide. To learn more about the difference between FDA-approved and non-FDA-approved cannabinoid products, please visit cannabinoidclinical.com.